• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND ARCHITECT TOTAL PSA

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND ARCHITECT TOTAL PSA Back to Search Results
Catalog Number 07K70-27
Device Problem High Test Results (2457)
Patient Problem No Known Impact Or Consequence To Patient (2692)
Event Date 08/29/2016
Event Type  malfunction  
Manufacturer Narrative
An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.This report is being filed on an international product, list number 7k70 that has a similar product distributed in the us, list number 6c06.
 
Event Description
The customer stated that the architect analyzer has generated falsely elevated total psa results on one patient.The results provided were: (b)(6) 2016 = 11.7 / (b)(6) 2016 = 2.5ng/ml / previous results at a different clinic were - (b)(6) 2014 = 20.1 / (b)(6) 2014 = 0.8.There was no reported impact to patient management.
 
Manufacturer Narrative
An evaluation was performed by reviewing the complaint text, reviewing other customer complaints for similar issues, accuracy testing, a review of labeling, and a review of historical records.The customer observed a potentially falsely elevated total psa result while using architect total psa reagent 7k70-25 lot 61499fn00.A review of complaints determined that there are no other complaints for this lot and no trends for the product.There was no patient sample available to assist in the investigation.Accuracy testing of a serum based panel was performed using a retained kit of lot 61499fn00.All specifications were met indicating that lot 61499fn00 is performing acceptably.A review of the manufacturing records did not identify any issues associated with the customer observation during the manufacturing of this lot.A review of labeling shows that there is adequate information provided to address the customer's issue of falsely elevated total psa results.Based on all available information and this investigation, the architect total psa reagent 7k70-25, lot 61499fn00, performed as intended and no product deficiency was identified.
 
Manufacturer Narrative
The device evaluation was reassessed and concluded that a malfunction occurred, therefore the device was not performing as intended.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT TOTAL PSA
Type of Device
TOTAL PSA
Manufacturer (Section D)
ABBOTT IRELAND
diagnostics division
finisklin business park
sligo NA
EI  NA
Manufacturer (Section G)
ABBOTT IRELAND
diagnostics division
finisklin business park
sligo NA
EI   NA
Manufacturer Contact
noemi romero-kondos, rn bsn
100 abbott park road
dept. 09b9, lccp1-3
abbott park, IL 60064-3537
224667-512
MDR Report Key6030895
MDR Text Key57490437
Report Number3008344661-2016-00066
Device Sequence Number1
Product Code MTF
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P910007
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Reporter Occupation Health Professional
Type of Report Initial,Followup,Followup
Report Date 05/30/2017
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received10/14/2016
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date01/19/2017
Device Catalogue Number07K70-27
Device Lot Number61499FN00
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received05/30/2017
Was Device Evaluated by Manufacturer? Yes
Date Device Manufactured02/01/2016
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
Treatment
SERIAL # (B)(4)
Patient Age63 YR
-
-